|Slideshows|September 16, 2020

4 Stages of Chronic Traumatic Encephalopathy

Author(s)Arman Fesharaki-Zadeh, MD, PhD

A 59-year-old man with a history of multiple concussions has been having a series of neurocognitive symptoms for the past several years. Discover more in this case.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

ByKim Do, PhD,Jessica Walters

June 3rd 2026

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

ByWilliam Li, MD,Morgan Hardy, MD

June 2nd 2026

Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting

ByLeah Kuntz,Guy Goodwin, MD

May 28th 2026

Phase 2b/3 Trial Evaluates Forvisirvat in Major Depressive Disorder

ByJoel Raskin, MD, FRCPC

May 28th 2026

Transdiagnostic Anhedonia: A Conversation With Roger S. McIntyre, MD, FRCPC

ByJohn J. Miller, MD,Roger S. McIntyre, MD, FRCPC

May 27th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

4 Stages of Chronic Traumatic Encephalopathy

Related Content

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data From the 2026 ASCP Annual Meeting

Phase 2b/3 Trial Evaluates Forvisirvat in Major Depressive Disorder

Transdiagnostic Anhedonia: A Conversation With Roger S. McIntyre, MD, FRCPC

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Endangered Education: Psychiatric Professional Degrees Under Attack

New Name, New Path for Psychiatry: The Future of the DSM

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability